Schering/Genome Therapeutics asthma collaboration valued at up to $67 mil..

Executive Summary

SCHERING/GENOME THERAPEUTICS ASTHMA AGREEMENT VALUED AT UP TO $67 MIL. will use genomics for the discovery of new asthma treatments. Waltham, Mass.-based Genome Therapeutics will use its high-throughput positional cloning, bioinformatics and genomics sequencing capabilities to identify genes and associated proteins for Schering-Plough to use in developing pharmaceuticals. Schering and Genome Therapeutics also have an anti-infectives research collaboration worth up to $43.5 mil. that was announced a year ago ("The Pink Sheet" Dec. 11, 1995, T&G-19).